Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 known ✓ | P22001 | 1/20 | 0.64 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.56 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.56 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.95 |
| ▸ | LTA4H | P09960 | 2/20 | 0.79 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43067 | 0.97 | TAAR1 (1.00) | TAAR1LTA4HPLA2G2AKCNA3SMN1; SMN2 | |
| Bromide SCHEMBL2762682 | 0.95 | TAAR1 (0.95) | TAAR1LTA4HPLA2G2AKCNA3SMN1; SMN2 | |
| Iodide SCHEMBL30108971 | 0.95 | TAAR1 (0.95) | TAAR1LTA4HPLA2G2AKCNA3SMN1; SMN2 | |
| Aniline SCHEMBL1567391 | 0.89 | TAAR1 (0.83) | TAAR1LTA4HPLA2G2AKCNA3SMN1; SMN2 | |
| SCHEMBL4653229 | 0.89 | LTA4H (1.00) | TAAR1LTA4HPLA2G2AKCNA3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3541189 | 0.88 | TAAR1 (0.74) | TAAR1LTA4HPLA2G2AKCNA3 | |
| Furan SCHEMBL28498789 | 0.87 | TAAR1 (0.79) | TAAR1LTA4HPLA2G2AKCNA3SMN1; SMN2 | |
| Hydroquinone SCHEMBL29195429 | 0.87 | TAAR1 (0.79) | TAAR1LTA4HPLA2G2AKCNA3ESR1 | |
| Hydrochloric Acid SCHEMBL9781678 | 0.87 | TAAR1 (0.72) | TAAR1LTA4HPLA2G2ASMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL7091202 | 0.86 | KCNA3 (0.73) | TAAR1LTA4HPLA2G2AKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433376-A | Preparation method of long-acting disinfection and sterilization fabric or fiber | 孙国明 | 2022-12-06 | — | — | CN | disclosed |
| CN-114403144-A | Quaternary ammonium salt composition for killing microorganisms and preparation method and application thereof | 广州蓝月亮实业有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-114403143-A | Anti-freezing quaternary ammonium salt composition and preparation method and application thereof | 广州蓝月亮实业有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-113881177-A | Antibacterial water-absorbing composite material, and preparation method and device thereof | 威高集团有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-108348605-A | Treatment of ER negative breast cancer with PDGF-CC inhibitors and antiestrogens | 帕拉卡林治疗公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-103610669-B | Di- (p-alkoxy benzene acrylketone) glutathione-S-transsulfurase latent inhibitor | 重庆医科大学 | 2018-03-27 | — | — | CN | disclosed |
| US-9278131-B2 | Process for lowering the viscosity of highly concentrated protein solutions | ADOCIA (FR) | 2016-03-08 | — | — | US | disclosed |
| US-20140044708-A1 | Process for lowering the viscosity of highly concentrated protein solutions | ADOCIA (FR) | 2014-02-13 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| EP-1054887-B1 | BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2000078737-A2 | ARYLOXY ETHYLAMINO TRIAZINES AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-28 | — | — | WO | disclosed |
| US-6051605-A | TREATING PSYCHOSIS AND SCHIZOPHRENIA USING A COMPOUND THAT IS AN ANTAGONIST OF DOPAMINE D4 RECEPTORS | WARNER-LAMBERT COMPANY (US) | 2000-04-18 | — | — | US | disclosed |
| US-5672588-A | Purine derivatives | NOVO NORDISK A/S (DK) | 1997-09-30 | — | — | US | disclosed |
| EP-0603348-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-06-29 | — | — | EP | disclosed |
| EP-0577746-A1 | IMPROVED PROCESS FOR PREPARING PHENYL CHLOROACETATE. | DU PONT (US) | 1994-01-12 | — | — | EP | disclosed |
| WO-1993023418-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-11-25 | — | — | WO | disclosed |
| CN-1066066-A | 2-aminopyrimidine-4-carboxamides derivatives, its synthetic method and application aspect medical | SYNTHELABO (FR) | 1992-11-11 | — | — | CN | disclosed |
| WO-1992016491-A1 | IMPROVED PROCESS FOR PREPARING PHENYL CHLOROACETATE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140044708-A1 | Process for lowering the viscosity of highly concentrated protein solutions | F13B, F5, F12 | KCNA3 3510/4885ESR1 4872/4885CYP19A1 4680/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | KCNA3 3044/4885ESR1 4268/4885CYP19A1 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.